What Does Brazil’s Report on Covaxin’s Safety Mean for India?

Recently on March 30, Brazil’s drug regulator ANVISA had rejected Bharat Biotech’s application for supplying Covaxin in the country. They claimed Bharat Biotech, the Hyderabad-based pharma company that is manufacturing this indigenous vaccine in India, has not taken adequate measures to completely kill or inactivate the virus. They also alleged a few other problems with the vaccine such as the possibility of variations in the potency and antigen quantity in the vaccine doses. All of which lack of a guarantee in how safe Covaxin is. And so Brazil decided to not go ahead and buy the 20 million Covaxin doses that it was planning to get until Bharat Biotech fixes these problems. But these irregularities that ANVISA is pointing out...why did the CDSCO not raise them before and also after these matters came to light why has it not taken any action? Also read: Brazil’s Report on Bharat Biotech Plant: Why is the CDSCO Silent? Host and Producer: Shorbori Purkayastha Guests: Priyanka Pulla, Bangalore-based science journalist Editor: Shelly Walia Music: Big Bang Fuzz Listen to The Big Story podcast on: Apple: https://apple.co/2AYdLIl Saavn: http://bit.ly/2oix78C Google Podcasts: http://bit.ly/2ntMV7S Spotify: https://spoti.fi/2IyLAUQ Deezer: http://bit.ly/2Vrf5Ng Castbox: http://bit.ly/2VqZ9ur Learn more about your ad choices. Visit megaphone.fm/adchoices